NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance

David C. Austin, Douglas W. Strand, Harold L. Love, Omar E. Franco, Magdalena M. Grabowska, Nicole L. Miller, Omar Hameed, Peter E. Clark, Robert J. Matusik, Ren J. Jin, Simon W. Hayward

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

BACKGROUND: Benign prostatic hyperplasia (BPH) is treated with 5α-reductase inhibitors (5ARI). These drugs inhibit the conversion of testosterone to dihydrotestosterone resulting in apoptosis and prostate shrinkage. Most patients initially respond to 5ARIs; however, failure is common especially in inflamed prostates, and often results in surgery. This communication examines a link between activation of NF-κB and increased expression of SRD5A2 as a potential mechanism by which patients fail 5ARI therapy. METHODS: Tissue was collected from “Surgical” patients, treated specifically for lower urinary tract symptoms secondary to advanced BPH; and, cancer free transition zone from “Incidental” patients treated for low grade, localized peripheral zone prostate cancer. Clinical, molecular and histopathological profiles were analyzed. Human prostatic stromal and epithelial cell lines were genetically modified to regulate NF-κB activity, androgen receptor (AR) full length (AR-FL), and AR variant 7 (AR-V7) expression. RESULTS: SRD5A2 is upregulated in advanced BPH. SRD5A2 was significantly associated with prostate volume determined by Transrectal Ultrasound (TRUS), and with more severe lower urinary tract symptoms (LUTS) determined by American Urological Association Symptom Score (AUASS). Synthesis of androgens was seen in cells in which NF-κB was activated. AR-FL and AR-V7 expression increased SRD5A2 expression while forced activation of NF-κB increased all three SRD5A isoforms. Knockdown of SRD5A2 in the epithelial cells resulted in significant reduction in proliferation, AR target gene expression, and response to testosterone (T). In tissue recombinants, canonical NF-κB activation in prostatic epithelium elevated all three SRD5A isoforms and resulted in in vivo growth under castrated conditions. CONCLUSION: Increased BPH severity in patients correlates with SRD5A2 expression. We demonstrate that NF-κB and AR-V7 upregulate SRD5A expression providing a mechanism to explain failure of 5ARI therapy in BPH patients. Prostate 76:1004–1018, 2016.

Original languageEnglish (US)
Pages (from-to)1004-1018
Number of pages15
JournalProstate
Volume76
Issue number11
DOIs
StatePublished - Aug 1 2016

Fingerprint

Androgen Receptors
Prostatic Hyperplasia
Protein Isoforms
Prostate
Lower Urinary Tract Symptoms
Testosterone
Prostatic Neoplasms
Epithelial Cells
Dihydrotestosterone
Stromal Cells
Androgens
Oxidoreductases
Up-Regulation
Epithelium
Apoptosis
Gene Expression
Cell Line
Therapeutics
Growth
Pharmaceutical Preparations

Keywords

  • androgen receptor
  • androgen receptor variant 7
  • BPH
  • inflammation
  • p65

ASJC Scopus subject areas

  • Urology
  • Oncology

Cite this

Austin, D. C., Strand, D. W., Love, H. L., Franco, O. E., Grabowska, M. M., Miller, N. L., ... Hayward, S. W. (2016). NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Prostate, 76(11), 1004-1018. https://doi.org/10.1002/pros.23195

NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. / Austin, David C.; Strand, Douglas W.; Love, Harold L.; Franco, Omar E.; Grabowska, Magdalena M.; Miller, Nicole L.; Hameed, Omar; Clark, Peter E.; Matusik, Robert J.; Jin, Ren J.; Hayward, Simon W.

In: Prostate, Vol. 76, No. 11, 01.08.2016, p. 1004-1018.

Research output: Contribution to journalArticle

Austin, DC, Strand, DW, Love, HL, Franco, OE, Grabowska, MM, Miller, NL, Hameed, O, Clark, PE, Matusik, RJ, Jin, RJ & Hayward, SW 2016, 'NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance', Prostate, vol. 76, no. 11, pp. 1004-1018. https://doi.org/10.1002/pros.23195
Austin, David C. ; Strand, Douglas W. ; Love, Harold L. ; Franco, Omar E. ; Grabowska, Magdalena M. ; Miller, Nicole L. ; Hameed, Omar ; Clark, Peter E. ; Matusik, Robert J. ; Jin, Ren J. ; Hayward, Simon W. / NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. In: Prostate. 2016 ; Vol. 76, No. 11. pp. 1004-1018.
@article{0bb46e7eb8e347a3a20c4053b8eef6df,
title = "NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance",
abstract = "BACKGROUND: Benign prostatic hyperplasia (BPH) is treated with 5α-reductase inhibitors (5ARI). These drugs inhibit the conversion of testosterone to dihydrotestosterone resulting in apoptosis and prostate shrinkage. Most patients initially respond to 5ARIs; however, failure is common especially in inflamed prostates, and often results in surgery. This communication examines a link between activation of NF-κB and increased expression of SRD5A2 as a potential mechanism by which patients fail 5ARI therapy. METHODS: Tissue was collected from “Surgical” patients, treated specifically for lower urinary tract symptoms secondary to advanced BPH; and, cancer free transition zone from “Incidental” patients treated for low grade, localized peripheral zone prostate cancer. Clinical, molecular and histopathological profiles were analyzed. Human prostatic stromal and epithelial cell lines were genetically modified to regulate NF-κB activity, androgen receptor (AR) full length (AR-FL), and AR variant 7 (AR-V7) expression. RESULTS: SRD5A2 is upregulated in advanced BPH. SRD5A2 was significantly associated with prostate volume determined by Transrectal Ultrasound (TRUS), and with more severe lower urinary tract symptoms (LUTS) determined by American Urological Association Symptom Score (AUASS). Synthesis of androgens was seen in cells in which NF-κB was activated. AR-FL and AR-V7 expression increased SRD5A2 expression while forced activation of NF-κB increased all three SRD5A isoforms. Knockdown of SRD5A2 in the epithelial cells resulted in significant reduction in proliferation, AR target gene expression, and response to testosterone (T). In tissue recombinants, canonical NF-κB activation in prostatic epithelium elevated all three SRD5A isoforms and resulted in in vivo growth under castrated conditions. CONCLUSION: Increased BPH severity in patients correlates with SRD5A2 expression. We demonstrate that NF-κB and AR-V7 upregulate SRD5A expression providing a mechanism to explain failure of 5ARI therapy in BPH patients. Prostate 76:1004–1018, 2016.",
keywords = "androgen receptor, androgen receptor variant 7, BPH, inflammation, p65",
author = "Austin, {David C.} and Strand, {Douglas W.} and Love, {Harold L.} and Franco, {Omar E.} and Grabowska, {Magdalena M.} and Miller, {Nicole L.} and Omar Hameed and Clark, {Peter E.} and Matusik, {Robert J.} and Jin, {Ren J.} and Hayward, {Simon W.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1002/pros.23195",
language = "English (US)",
volume = "76",
pages = "1004--1018",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance

AU - Austin, David C.

AU - Strand, Douglas W.

AU - Love, Harold L.

AU - Franco, Omar E.

AU - Grabowska, Magdalena M.

AU - Miller, Nicole L.

AU - Hameed, Omar

AU - Clark, Peter E.

AU - Matusik, Robert J.

AU - Jin, Ren J.

AU - Hayward, Simon W.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - BACKGROUND: Benign prostatic hyperplasia (BPH) is treated with 5α-reductase inhibitors (5ARI). These drugs inhibit the conversion of testosterone to dihydrotestosterone resulting in apoptosis and prostate shrinkage. Most patients initially respond to 5ARIs; however, failure is common especially in inflamed prostates, and often results in surgery. This communication examines a link between activation of NF-κB and increased expression of SRD5A2 as a potential mechanism by which patients fail 5ARI therapy. METHODS: Tissue was collected from “Surgical” patients, treated specifically for lower urinary tract symptoms secondary to advanced BPH; and, cancer free transition zone from “Incidental” patients treated for low grade, localized peripheral zone prostate cancer. Clinical, molecular and histopathological profiles were analyzed. Human prostatic stromal and epithelial cell lines were genetically modified to regulate NF-κB activity, androgen receptor (AR) full length (AR-FL), and AR variant 7 (AR-V7) expression. RESULTS: SRD5A2 is upregulated in advanced BPH. SRD5A2 was significantly associated with prostate volume determined by Transrectal Ultrasound (TRUS), and with more severe lower urinary tract symptoms (LUTS) determined by American Urological Association Symptom Score (AUASS). Synthesis of androgens was seen in cells in which NF-κB was activated. AR-FL and AR-V7 expression increased SRD5A2 expression while forced activation of NF-κB increased all three SRD5A isoforms. Knockdown of SRD5A2 in the epithelial cells resulted in significant reduction in proliferation, AR target gene expression, and response to testosterone (T). In tissue recombinants, canonical NF-κB activation in prostatic epithelium elevated all three SRD5A isoforms and resulted in in vivo growth under castrated conditions. CONCLUSION: Increased BPH severity in patients correlates with SRD5A2 expression. We demonstrate that NF-κB and AR-V7 upregulate SRD5A expression providing a mechanism to explain failure of 5ARI therapy in BPH patients. Prostate 76:1004–1018, 2016.

AB - BACKGROUND: Benign prostatic hyperplasia (BPH) is treated with 5α-reductase inhibitors (5ARI). These drugs inhibit the conversion of testosterone to dihydrotestosterone resulting in apoptosis and prostate shrinkage. Most patients initially respond to 5ARIs; however, failure is common especially in inflamed prostates, and often results in surgery. This communication examines a link between activation of NF-κB and increased expression of SRD5A2 as a potential mechanism by which patients fail 5ARI therapy. METHODS: Tissue was collected from “Surgical” patients, treated specifically for lower urinary tract symptoms secondary to advanced BPH; and, cancer free transition zone from “Incidental” patients treated for low grade, localized peripheral zone prostate cancer. Clinical, molecular and histopathological profiles were analyzed. Human prostatic stromal and epithelial cell lines were genetically modified to regulate NF-κB activity, androgen receptor (AR) full length (AR-FL), and AR variant 7 (AR-V7) expression. RESULTS: SRD5A2 is upregulated in advanced BPH. SRD5A2 was significantly associated with prostate volume determined by Transrectal Ultrasound (TRUS), and with more severe lower urinary tract symptoms (LUTS) determined by American Urological Association Symptom Score (AUASS). Synthesis of androgens was seen in cells in which NF-κB was activated. AR-FL and AR-V7 expression increased SRD5A2 expression while forced activation of NF-κB increased all three SRD5A isoforms. Knockdown of SRD5A2 in the epithelial cells resulted in significant reduction in proliferation, AR target gene expression, and response to testosterone (T). In tissue recombinants, canonical NF-κB activation in prostatic epithelium elevated all three SRD5A isoforms and resulted in in vivo growth under castrated conditions. CONCLUSION: Increased BPH severity in patients correlates with SRD5A2 expression. We demonstrate that NF-κB and AR-V7 upregulate SRD5A expression providing a mechanism to explain failure of 5ARI therapy in BPH patients. Prostate 76:1004–1018, 2016.

KW - androgen receptor

KW - androgen receptor variant 7

KW - BPH

KW - inflammation

KW - p65

UR - http://www.scopus.com/inward/record.url?scp=84975167820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975167820&partnerID=8YFLogxK

U2 - 10.1002/pros.23195

DO - 10.1002/pros.23195

M3 - Article

C2 - 27197599

AN - SCOPUS:84975167820

VL - 76

SP - 1004

EP - 1018

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 11

ER -